公开(公告)号：US20240075029A1

公开(公告)日：2024-03-07

申请号：US18255262

申请日：2021-12-01

申请人： METRIOPHARM AG

发明人： Wolfgang BRYSCH ,  Astrid KAISER ,  Petra SCHULZ ,  Sara SCHUMANN ,  Jörg WEGERER

IPC分类号： A61K31/502 ,  A61K45/06 ,  A61P31/14

CPC分类号： A61K31/502 ,  A61K45/06 ,  A61P31/14

摘要： The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.

公开(公告)号：US12122753B2

公开(公告)日：2024-10-22

申请号：US16961230

申请日：2019-01-10

申请人： MetrioPharm AG

发明人： Ingo Saar ,  Wolfgang Brysch ,  Jörg von Wegerer

IPC分类号： C07D237/32 ,  A61K47/22 ,  A61K9/00

CPC分类号： C07D237/32 ,  A61K47/22 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053

摘要： The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.

公开(公告)号：US20230218614A1

公开(公告)日：2023-07-13

申请号：US18001034

申请日：2021-06-09

申请人： METRIOPHARM AG

发明人： Wolfgang BRYSCH ,  Astrid KAISER ,  Petra SCHULZ ,  Sara SCHUMANN ,  Jörg VON WEGERER ,  Christian SETZ ,  Ulrich SCHUBERT

IPC分类号： A61K31/502 ,  A61P31/14 ,  A61K45/06

CPC分类号： A61K31/502 ,  A61K45/06 ,  A61P31/14

摘要： The present application relates to the use of a phthalazinedione in the prevention or treatment of coronaviral infections. Pharmaceutical compositions, combinations and advantageous formulation techniques are disclosed.

公开(公告)号：US20230053455A1

公开(公告)日：2023-02-23

申请号：US17791460

申请日：2021-01-29

申请人： Metriopharm AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Petra Schulz ,  Sara Schumann ,  Jörg von Wegerer

IPC分类号： A61K31/502 ,  A61P11/00

摘要： The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

公开(公告)号：US11007192B2

公开(公告)日：2021-05-18

申请号：US16347171

申请日：2017-11-06

申请人： METRIOPHARM AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Claudia Van Laak ,  Beate Ludescher ,  Maliha Shah ,  Jörg Von Wegerer

IPC分类号： A61K31/502 ,  A61K9/00 ,  A61P25/28

摘要： The invention relates to 5-amino-2,3-dihydro-1,4-phthalazinedione or related compounds, compositions or combinations thereof, for use in the treatment of chronic progressive multiple sclerosis, in particular primary and secondary progressive multiple sclerosis. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

公开(公告)号：US20210061771A1

公开(公告)日：2021-03-04

申请号：US16961230

申请日：2019-01-10

申请人： MetrioPharm AG

发明人： Ingo Saar ,  Wolfgang Brysch

IPC分类号： C07D237/32 ,  A61K47/22

摘要： The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.

公开(公告)号：US09079863B2

公开(公告)日：2015-07-14

申请号：US14247626

申请日：2014-04-08

申请人： METRIOPHARM AG

发明人： Josef Breu ,  Wolfgang Brysch ,  Astrid Kaiser ,  Beate Ludescher ,  Gerrit Maass ,  Thomas Martin ,  Wolfgang Milius ,  Michael Niedermaier

IPC分类号： C07D237/30 ,  A61K31/50 ,  A01N43/58 ,  C07D237/32

CPC分类号： C07D237/32

摘要： The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.

摘要翻译： 本发明涉及为5-氨基-2,3-二氢酞嗪-1,4-二酮钠盐提供两种新的结晶形式I和II。 令人惊讶的是，发现I型和II型具有不同的免疫学作用。 这种有利的性质可用于免疫特异性应用。 此外，两种形式都具有有利的物理化学性质，其可用于生产，进一步加工和/或使用I型或II型药物制剂或两者的混合物。

公开(公告)号：US20230241060A1

公开(公告)日：2023-08-03

申请号：US18004806

申请日：2021-07-08

申请人： METRIOPHARM AG

发明人： Wolfgang BRYSCH ,  Jörg VON WEGERER ,  Beatte LUDESCHER ,  Sara SCHUMANN ,  Astrid KAISER ,  Petra SCHULZ

IPC分类号： A61K31/502 ,  A61K31/573 ,  A61P1/00 ,  A61P19/02 ,  A61P29/00

CPC分类号： A61K31/502 ,  A61K31/573 ,  A61P1/00 ,  A61P19/02 ,  A61P29/00

摘要： 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts for use as corticoid-sparing agent and pharmaceutical combinations comprising said glucocorticoid-sparing agent and a glucocorticoid for use in the prophylaxis and/or treatment of conditions or diseases usually treated with glucocorticoids are disclosed, as well as suitable application forms, pharmaceutical compositions and their prophylactic or therapeutic uses.

公开(公告)号：US20230113516A1

公开(公告)日：2023-04-13

申请号：US17913687

申请日：2021-03-24

申请人： Metriopharm AG

发明人： Wolfgang Brysch ,  Astrid Kaiser ,  Petra Schulz ,  Sara Schumann ,  Jörg von Wegerer ,  Christian Setz ,  Ulrich Schubert

IPC分类号： A61K31/502 ,  A61K45/06 ,  A61P11/00

摘要： The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the prevention or treatment of acute lung injury. The invention in particular relates to the use of 5-amino-2, 3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

公开(公告)号：US11203575B2

公开(公告)日：2021-12-21

申请号：US15999050

申请日：2017-02-15

申请人： METRIOPHARM AG

发明人： Thomas Martin ,  Josef Breu ,  Juliane Fleissner ,  Wolfgang Brysch ,  Jörg Von Wegerer

IPC分类号： C07D237/32 ,  A61K9/00 ,  A61K9/12 ,  A61K45/06

摘要： A new method for producing a crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.